(R)-N-(2-((1-苄基吡咯-3-基)氨基)-2-氧乙基)-3-(三氟甲基)苯甲酰胺 | 226228-88-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (R)-N-(2-((1-苄基吡咯-3-基)氨基)-2-氧乙基)-3-(三氟甲基)苯甲酰胺
• 英文名称: (R)-N-(2-(1-benzylpyrrolidin-3-ylamino)-2-oxoethyl)-3-(trifluoromethyl)benzamide
• 英文别名: N-[(1-benzylpyrrolidine-(3R)-yl-carbamoyl)-methyl]-3-trifluoromethylbenzamide；Benzamide, N-[2-oxo-2-[[(3R)-1-(phenylmethyl)-3-pyrrolidinyl]amino]ethyl]-3-(trifluoromethyl)-；N-[2-[[(3R)-1-benzylpyrrolidin-3-yl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide
• CAS: 226228-88-2
• 化学式: C₂₁H₂₂F₃N₃O₂
• 分子量: 405.42
• InChiKey: FAAVOKBSFIJHRY-GOSISDBHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  61.4
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (R)-N-(2-((1-苄基吡咯-3-基)氨基)-2-氧乙基)-3-(三氟甲基)苯甲酰胺 在 palladium(II) hydroxide 盐酸 、 氢气 、 potassium carbonate 作用下， 以 甲醇 、 乙醇 、 乙腈 为溶剂， 20.0~80.0 ℃ 、101.33 kPa 条件下， 反应 25.5h， 生成 N-{[1-(2-(piperazine-1-yl)ethyl)-pyrrolidine-(3R)-yl-carbamoyl]-methyl}-3-trifluoromethylbenzamide hydrochloride
  参考文献：
  名称：

  PIPERAZINYL 3-AMINOPYRROLIDINE DERIVATIVES AS A CCR2 ANTAGONIST

  摘要：

  本发明涉及化学式1的化合物及其具有CCR2（趋化因子受体2）拮抗作用的盐或异构体。这些化合物对于治疗、预防或缓解类风湿性关节炎、动脉硬化、多发性硬化症、哮喘以及与CCR2相关的各种疾病非常有用。其中R1、R2、R3、R4、R5、R6、R7、R8和R9的定义与说明书中相同。

  公开号：

  US20120190689A1
• 作为产物：
  描述：

  间三氟甲基马尿酸 在 N-甲基吗啉 作用下， 以 四氢呋喃 为溶剂， 反应 1.58h， 生成 (R)-N-(2-((1-苄基吡咯-3-基)氨基)-2-氧乙基)-3-(三氟甲基)苯甲酰胺
  参考文献：
  名称：

  Discovery of INCB3284, a Potent, Selective, and Orally Bioavailable hCCR2 Antagonist

  摘要：

  We report the identification of 13 (INCB3284) as a potent human CCR2 (hCCR2) antagonist. INCB3284 exhibited an IC50 of 3.7 nM in antagonism of monocyte chemoattractant protein-1 binding to hCCR2, an IC50 of 4.7 nM in antagonism of chemotaxis activity, an IC50 of 84 mu M in inhibition of the hERG potassium current, a free fraction of 58% in protein binding, high selectivity over other chemokine receptors and G-protein-coupled receptors, and acceptable oral bioavailability in rodents and primates. In human clinical trials, INCB3284 exhibited a pharmacokinetic profile suitable for once-a-day dosing (T-1/2 = 15 h).

  DOI：

  10.1021/ml200030q

文献信息

• 3-Aminopyrrolidine derivaties as modulators of chemokine receptors
  申请人：Xue Chu-Biao

  公开号：US20060252751A1

  公开（公告）日：2006-11-09

  The present invention relates to 3-aminopyrrolidine derivatives of the formula I: (wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , X, Y and X are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as a modulator of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.

  本发明涉及式I的3-氨基吡咯烷衍生物（其中R1、R2、R3、R4、R5、R6、R7、R8、X、Y和X的定义如本文所述），它们可用作趋化因子受体活性调节剂。特别地，这些化合物可用作趋化因子受体的调节剂，更具体地作为CCR2和/或CCR5受体的调节剂。该发明的化合物和组合物可以结合趋化因子受体，例如CCR2和/或CCR5趋化因子受体，并用于治疗与趋化因子（例如CCR2和/或CCR5）活性相关的疾病，如动脉粥样硬化、再狭窄、狼疮、器官移植排斥和类风湿性关节炎。
• 3-Aminopyrrolidine Derivatives As Modulators Of Chemokine Receptors
  申请人：Xue Chu-Biao

  公开号：US20090247474A1

  公开（公告）日：2009-10-01

  The present invention relates to 3-aminopyrrolidine derivatives of the formula I: (wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , X, Y and X are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as a modulator of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.

  本发明涉及公式I的3-氨基吡咯烷衍生物（其中R1、R2、R3、R4、R5、R6、R7、R8、X、Y和X如本文所定义），其可用作趋化因子受体活性调节剂。特别地，这些化合物可用作趋化因子受体的调节剂，更具体地作为CCR2和/或CCR5受体的调节剂。本发明的化合物和组合物可以结合趋化因子受体，例如CCR2和/或CCR5趋化因子受体，并且可用于治疗与趋化因子，例如CCR2和/或CCR5活性相关的疾病，例如动脉粥样硬化、再狭窄、狼疮、器官移植排斥和类风湿性关节炎。
• 3-aminopyrrolidine derivatives as modulators of chemokine receptors
  申请人：Incyte Corporation

  公开号：US07985730B2

  公开（公告）日：2011-07-26

  The present invention relates to 3-aminopyrrolidine derivatives of the formula I: (wherein R1, R2, R3, R4, R5, R6, R7, R8, X, Y and X are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as a modulator of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.

  本发明涉及式I的3-氨基吡咯烷衍生物（其中R1、R2、R3、R4、R5、R6、R7、R8、X、Y和X如本文所定义），它们可用作趋化因子受体活性调节剂。特别地，这些化合物可用作趋化因子受体的调节剂，更具体地说，可用作CCR2和/或CCR5受体的调节剂。本发明的化合物和组合物可以结合趋化因子受体，例如CCR2和/或CCR5趋化因子受体，并且可用于治疗与趋化因子（例如CCR2和/或CCR5）活性相关的疾病，例如动脉粥样硬化、再狭窄、狼疮、器官移植排斥和类风湿性关节炎。
• 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS
  申请人：Xue Chu-Biao

  公开号：US20110251168A1

  公开（公告）日：2011-10-13

  The present invention relates to 3-aminopyrrolidine derivatives of the formula I: (wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , X, Y and X are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as a modulator of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.

  本发明涉及式I的3-氨基吡咯烷衍生物（其中R1、R2、R3、R4、R5、R6、R7、R8、X、Y和X如本文所定义），其可用作趋化因子受体活性调节剂。特别地，这些化合物可用作趋化因子受体的调节剂，更具体地，可用作CCR2和/或CCR5受体的调节剂。本发明的化合物和组合物可结合趋化因子受体，例如CCR2和/或CCR5趋化因子受体，并且可用于治疗与趋化因子（例如CCR2和/或CCR5）活性相关的疾病，例如动脉粥样硬化、再狭窄、狼疮、器官移植排斥和类风湿性关节炎。
• 3-Aminopyrrolidine Derivatives as Modulators of Chemokine Receptors
  申请人：Incyte Corporation

  公开号：EP2431357A2

  公开（公告）日：2012-03-21

  The present invention relates to 3-aminopyrrolidine derivatives of the formula I: (wherein R1, R2, R3, R4, R5, R6, R7, R8, X, Y and X are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as a modulator of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.

  本发明涉及式 I 的 3-氨基吡咯烷衍生物： (其中 R1、R2、R3、R4、R5、R6、R7、R8、X、Y 和 X 如本文所定义）的 3-氨基吡咯烷衍生物，它们可用作趋化因子受体活性的调节剂。特别是，这些化合物可用作趋化因子受体的调节剂，更具体地说，可用作 CCR2 和/或 CCR5 受体的调节剂。本发明的化合物和组合物可与趋化因子受体结合，如CCR2和/或CCR5趋化因子受体，可用于治疗与趋化因子（如CCR2和/或CCR5）活性相关的疾病，如动脉粥样硬化、再狭窄、狼疮、器官移植排斥反应和类风湿性关节炎。